• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Voodoo Medicine: Time To Stop
The world's most celebrated athlete standing on the podium in Rio in honor of receiving yet another gold medal has something important in common with your lazy uncle throwing back a cold one in his Barcalounger. Yes, swimming powerhouse Michael Phelps, purple-spotted from cupping therapy, and your slovenly relative with a beer gut both share a bond -- a weakness in succumbing to the allure of voodoo medicine. Modern-day snake oil salesmen hawking quick cures and TV doctors peddling the latest diet miracle with blatantly ridiculous claims are everywhere on the tube, social media, the supermarket and old-fashioned billboards...
Source: Science - The Huffington Post - August 12, 2016 Category: Science Source Type: news

Rooibos: Better Than Green Tea For Many Reasons
When I hiked Table Mountain on my last trip to South Africa, the locals told me about an herb that is better than green tea that kept them disease-free. African Bushmen have used this herb since before recorded history, but it’s still pretty rare here in America. Studies on this plant are being done all over the world. But not in the U.S. Because Big Pharma and the FDA aren’t interested in a natural cure that can’t be patented — or profited from. What is This South African Herb? I’m talking about an herb called Rooibos — or red bush in Afrikaans. Rooibos (pronounced roy-boss) provides a whole lo...
Source: Al Sears, MD Natural Remedies - May 27, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Turmeric: Nature ’s Miracle Root for Disease
My friends Lelir and Westi in Bali don’t like to go to doctors. Nature is their pharmacy. You see, Lelir is a Balian. That means “herbal healer.” And Westi’s plantation is bursting with healing plants.  But one plant stands out above all the others. Lelir uses it to make a daily immune-boosting elixir as well as an anti-aging facial scrub. Balians use it as an antibiotic and for liver support. They boil it with milk and sugar to treat the common cold and allergies. Rural doctors make it into a paste with lime to ease sore joints. They make drinks to treat fevers and stomach pain. They mix it wi...
Source: Al Sears, MD Natural Remedies - September 20, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Evidence Base of Clinical Studies on Qi Gong: A Bibliometric Analysis.
CONCLUSIONS: Qigong research publications have been increasing gradually. Reports on study types, participants, Qigong Intervention, and outcomes are diverse and inconsistent. There is an urgent need to develop a set of reporting standards for various interventions of Qigong. Further trials of high methodological quality with sufficient sample size and real world studies are needed to verify the effects of Qigong in health and disease management. PMID: 32444061 [PubMed - as supplied by publisher]
Source: Complementary Therapies in Medicine - April 30, 2020 Category: Complementary Medicine Authors: Zhang YP, Hu RX, Han M, Lai BY, Liang SB, Chen BJ, Robinson N, Chen K, Liu JP Tags: Complement Ther Med Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news